Statistical Power Clause Samples

The Statistical Power clause defines the minimum probability that a study or analysis will detect an effect if one truly exists. In practice, this clause typically requires that research or testing methodologies are designed to achieve a specified statistical power level, such as 80% or 90%, ensuring that the sample size and study design are adequate. Its core function is to ensure the reliability and validity of study results by minimizing the risk of false negatives, thereby supporting sound decision-making based on the data collected.
Statistical Power. The study had 51% statistical power to detect an absolute difference of 30 percentage points between the PVI and IC groups’ rates of virologic suppression at a 5% significance level for a two-sided test. Comparing the IC and PC arms, the study had 67% power to detect the same difference. We used logistic regression to estimate the unadjusted and adjusted impact of the IC treatment relative to the PVI arm and relative to the PC arm. The predictor variables included treatment arm indicators and the stratifying variable. Our hypothesis tests were constructed relying on the asymptotic normality of the maximum likelihood estimator, but we obtained similar results when we conducted permutation tests. All statistical procedures were implemented using Stata 13 (StataCorp, College Station, TX, USA). Supplementary analyses indicate that the three arms had similar demographic and clinical characteristics at baseline, although individuals in the PC arm were older (median age 48.93 years) than individuals in the IC arm (median 40.10) and PVI arm (median 42.88). Individuals in the IC arm had higher pVL values leading up to the enrollment visit relative to individuals in the other arms. The PC arm had a higher rate of missing pVL measurements at the fifth study visit compared to the other arms. In the IC arm, 48% of participants had at least one suppressed viral load measurement across the three visits prior to the enrollment visit. The percentage was 43% in the PVI arm and 36% in the PC arm. Thus, many individuals in the study had experienced some previous success in achieving viral suppression, although some individuals in the study had faced much more difficulty achieving success in the past.
View SourceView Similar (2)
Statistical Power. This study is a pilot investigation intended to estimate effect sizes of the safety and efficacy of MDMA-assisted psychotherapy in people with PTSD. Because of their exploratory nature, pilot studies are often underpowered for detecting the desired effect. Because it is a pilot study in a small sample, statistical power is difficult to assess but it is likely to be low. Analyses of MAPS’ completed US study of MDMA-assisted psychotherapy in 20 people with PTSD found an effect size of 1.24 for treatment efficacy, as represented by changes in CAPS score [77]. The estimated effect size for this study may be lower as a result of comparing the full dose of MDMA with a comparator dose of MDMA instead of with inactive placebo. The sponsor intends to combine effect size estimates to develop a dose response curve as a meta-analyses of CAPS scores across MAPS-sponsored pilot studies. The sponsor used Java applications created by ▇▇▇▇▇ and posted on the website listed below to calculate estimated statistical power for this study, assuming an effect size of 0.75 for the impact of two sessions of MDMA-assisted psychotherapy on symptoms [169], reducing the effect size to account for the hypothesized effects of using a comparator dose. The software calculated an estimated power of 0.21, indicating an underpowered study. Had we used the higher effect size of 1.1, power analysis still indicates that this study is underpowered, with an estimated effect size of 0.37. Statistical power estimates were not available for secondary and exploratory measures, as they were previously not used in sponsor-supported studies.
View Source
Statistical Power. This is a pilot study intended to collect estimates of effect size of Full dose (125mg) MDMA compared to Low dose (40mg)
View Source

Related to Statistical Power

  • Statistical Data The statistical, industry-related and market-related data included in the Registration Statement, the Sale Preliminary Prospectus, and/or the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate, and such data materially agree with the sources from which they are derived.

  • Statistical Information Any third-party statistical and market-related data included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material respects.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌

  • Statistics The Parties shall endeavour to promote, in accordance with existing statistical cooperation activities between the Union and ASEAN, the harmonisation of statistical methods and practices including the gathering and dissemination of statistics, thus enabling them to use, on a mutually acceptable basis, statistics on trade in goods and services, foreign direct investment and, more generally, on any other area covered by this Agreement which lends itself to statistical data collection, processing, analysis and dissemination.

  • Statistical, Demographic or Market-Related Data All statistical, demographic or market-related data included in the Registration Statement, the Disclosure Package or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate and all such data included in the Registration Statement, the Disclosure Package or the Prospectus accurately reflects the materials upon which it is based or from which it was derived.